For the quarter ending 2026-03-31.
| Income Statement | 2026-03-31 |
|---|---|
| Research and development | 33,955 |
| General and administrative | 18,856 |
| Total operating expenses | 52,811 |
| Loss from operations | -52,811 |
| Interest income | 2,328 |
| Other expense, net | -1 |
| Total other income, net | 2,327 |
| Net loss | -50,484 |
| Unrealized loss on available-for-sale securities | -122 |
| Comprehensive loss | -50,606 |
First Tracks Biotherapeutics, Inc. (TRAX)
First Tracks Biotherapeutics, Inc. (TRAX)